Patents by Inventor Steven A. Titus
Steven A. Titus has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240132160Abstract: A component for a vehicle includes a skid plate configured to attach to an underbody of the vehicle, a plurality of cooling channels extending in a longitudinal direction between the skid plate and the underbody of the vehicle, and a structural reinforcement extending outward from the skid plate. The skid plate, the plurality of cooling channels, and the structural reinforcement are additively manufactured in a unitary construction.Type: ApplicationFiled: October 18, 2022Publication date: April 25, 2024Applicant: Ford Global Technologies, LLCInventors: Keith Weston, Jim Stevens, David D. Friske, Mark Meinhart, Matthew Arthur Titus
-
Patent number: 10301314Abstract: The disclosure provides compounds for reducing the prevalence of the perinucleolar compartment in cells, for example, of formula (I), wherein R1, R2, R3, and R4 are as defined herein, that are useful in treating a disease or disorder associated with increased prevalence of the perinucleolar compartment, such as cancer. Also disclosed is a composition containing a pharmaceutically acceptable carrier and at least one compound embodying the principles of the invention, and a method of treating or preventing cancer in a mammal.Type: GrantFiled: May 26, 2017Date of Patent: May 28, 2019Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, University of Kansas, Northwestern UniversityInventors: Kevin Frankowski, Samarjit Patnaik, Sui Huang, Juan Jose Marugan, John Norton, Frank J. Schoenen, Noel Terrence Southall, Steven Titus, Wei Zheng, Chen Wang
-
Publication number: 20170260192Abstract: The disclosure provides compounds for reducing the prevalence of the perinucleolar compartment in cells, for example, of formula (I), wherein R1, R2, R3, and R4 are as defined herein, that are useful in treating a disease or disorder associated with increased prevalence of the perinucleolar compartment, such as cancer. Also disclosed is a composition containing a pharmaceutically acceptable carrier and at least one compound embodying the principles of the invention, and a method of treating or preventing cancer in a mammal.Type: ApplicationFiled: May 26, 2017Publication date: September 14, 2017Applicants: The United States of America, as represented by the Secretary, Dept of Health and Human Services, University of Kansas, Northwestern UniversityInventors: Kevin Frankowski, Samarjit Patnaik, Sui Huang, Juan Jose Marugan, John Norton, Frank J. Schoenen, Noel Terrence Southall, Steven Titus, Wei Zheng
-
Patent number: 9663521Abstract: The disclosure provides compounds for reducing the prevalence of the perinucleolar compartment in cells, for example, of formula (I), wherein R1, R2, R3, and R4 are as defined herein, that are useful in treating a disease or disorder associated with increased prevalence of the perinucleolar compartment, such as cancer. Also disclosed is a composition containing a pharmaceutically acceptable carrier and at least one compound embodying the principles of the invention, and a method of treating or preventing cancer in a mammal.Type: GrantFiled: December 17, 2012Date of Patent: May 30, 2017Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, University of Kansas, Northwestern UniversityInventors: Kevin Frankowski, Samarjit Patnaik, Sui Huang, Juan Jose Marugan, John Norton, Frank J. Schoenen, Noel Terrence Southall, Steven Titus, Wei Zheng
-
Patent number: 9458141Abstract: Disclosed are oxo-hydroquinazolines that are useful as selective TSHR agonists. The compounds may be used for detecting or treating thyroid cancer, or treating a bone degenerative disorder.Type: GrantFiled: September 29, 2015Date of Patent: October 4, 2016Assignees: The United States of America, as Represented by the Secretary, Department of Health and Human Services, Forschungsverbund Berlin, E.V.Inventors: Marvin C. Gershengorn, Susanne Neumann, Bruce M. Raaka, Craig J. Thomas, James Inglese, Noel T. Southall, Steven Titus, Wei Zheng, Wenwei Huang, Gerd Krause, Gunnar Kleinau
-
Patent number: 9296729Abstract: Disclosed are oxo-hydroquinazolines that are useful as selective TSHR agonists. The compounds may be used for detecting or treating thyroid cancer, or treating a bone degenerative disorder.Type: GrantFiled: April 2, 2014Date of Patent: March 29, 2016Assignees: The United States of America as Represented by the Secretary of the Department of Health and Human Services, Forschungsverbund Berlin E.V.Inventors: Marvin C. Gershengorn, Susanne Neumann, Bruce M. Raaka, Craig J. Thomas, James Inglese, Noel T. Southall, Steven Titus, Wenwei Huang, Gerd Krause, Gunnar Kleinau, Wei Zheng
-
Publication number: 20160024023Abstract: Disclosed are oxo-hydroquinazolines that are useful as selective TSHR agonists. The compounds may be used for detecting or treating thyroid cancer, or treating a bone degenerative disorder.Type: ApplicationFiled: September 29, 2015Publication date: January 28, 2016Applicants: Health and Human Services, Forschungsverbund Berlin E.V.Inventors: Marvin C. Gershengorn, Susanne Neumann, Bruce M. Raaka, Craig J. Thomas, James Inglese, Noel T. Southall, Steven Titus, Wei Zheng, Wenwei Huang, Gerd Krause, Gunnar Kleinau
-
Patent number: 9187457Abstract: Disclosed are oxo-hydroquinazolines that are useful as selective TSHR agonists. The compounds may be used for detecting or treating thyroid cancer, or treating a bone degenerative disorder.Type: GrantFiled: May 17, 2013Date of Patent: November 17, 2015Assignees: The United States of America as represented by the Secretary of the Department of Health and Human Services, Forschungsverbund Berlin E.V.Inventors: Marvin C. Gershengorn, Susanne Neumann, Bruce M. Raaka, Craig J. Thomas, James Inglese, Noel T. Southall, Steven Titus, Wei Zheng, Wenwei Huang, Gerd Krause, Gunnar Kleinau
-
Publication number: 20140323438Abstract: The disclosure provides compounds for reducing the prevalence of the perinucleolar compartment in cells, for example, of formula (I), wherein R1, R2, R3, and R4 are as defined herein, that are useful in treating a disease or disorder associated with increased prevalence of the perinucleolar compartment, such as cancer. Also disclosed is a composition containing a pharmaceutically acceptable carrier and at least one compound embodying the principles of the invention, and a method of treating or preventing cancer in a mammal.Type: ApplicationFiled: December 17, 2012Publication date: October 30, 2014Inventors: Kevin Frankowski, Samarjit Patnaik, Sui Huang, Juan Jose Marugan, John Norton, Frank J. Schoenen, Noel Terrence Southall, Steven Titus, Wei Zheng
-
Publication number: 20140301944Abstract: Disclosed are oxo-hydroquinazolines that are useful as selective TSHR agonists. The compounds may be used for detecting or treating thyroid cancer, or treating a bone degenerative disorder.Type: ApplicationFiled: April 2, 2014Publication date: October 9, 2014Applicants: Forschungsverbund Berlin E.V., The United States of America, as represented by the Secretary, Department of Health and Human ServInventors: Marvin C. Gershengorn, Susanne Neumann, Bruce M. Raaka, Craig J. Thomas, James Inglese, Noel T. Southall, Steven Titus, Wenwei Huang, Gerd Krause, Gunnar Kleinau, Wei Zheng
-
Patent number: 8741259Abstract: Disclosed are oxo-hydroquinazolines that are useful as selective TSHR agonists. The compounds may be used for detecting or treating thyroid cancer, or treating a bone degenerative disorder.Type: GrantFiled: October 20, 2008Date of Patent: June 3, 2014Inventors: Marvin C. Gershengorn, Susanne Neumann, Bruce M. Raaka, Craig J. Thomas, James Inglese, Noel T. Southall, Steven Titus, Wei Zheng, Wenwei Huang, Gerd Krause, Gunnar Kleinau
-
Publication number: 20130251631Abstract: Disclosed are oxo-hydroquinazolines that are useful as selective TSHR agonists. The compounds may be used for detecting or treating thyroid cancer, or treating a bone degenerative disorder.Type: ApplicationFiled: May 17, 2013Publication date: September 26, 2013Applicants: Forschungsverbund Berlin E.V., The Government of the United States of America as represented by the Secretary of the Department ofInventors: Marvin C. Gershengorn, Susanne Neumann, Bruce M. Raaka, Craig J. Thomas, James Inglese, Noel T. Southall, Steven Titus, Wei Zheng, Wenwei Huang, Gerd Krause, Gunnar Kleinau
-
Publication number: 20130096160Abstract: Aryl substituted thiazol-2-yl-piperidines and related compounds useful as modulators of survival motor neuron (SMN) protein production are provided herein. Without being bound to any particular theory it is believed the aryl substituted thiazol-2-yl-piperidines and related compounds provided herein act to increase production of the SMN2 form of survival motor neuron protein. These compounds are useful for treating spinal muscular atrophy. Pharmaceutical compositions containing a carrier and one or more of the aryl substituted thiazol-2-yl-piperidine or related compounds described herein are also provided. Methods of treating spinal muscular atrophy are also provided by this disclosure.Type: ApplicationFiled: April 14, 2011Publication date: April 18, 2013Applicants: Secretary, Department of Health and Human ServicesInventors: Juan Jose Marugan, Jingbo Xiao, Steven A. Titus, Noel Southall, Wei Zheng, Elliot J. Androphy, Jonathan Cherry
-
Publication number: 20110195018Abstract: Disclosed are oxo-hydroquinazolines that are useful as selective TSHR agonists. The compounds may be used for detecting or treating thyroid cancer, or treating a bone degenerative disorder.Type: ApplicationFiled: October 20, 2008Publication date: August 11, 2011Inventors: Marvin C. Gershengorn, Susanne Neumann, Bruce M. Raaka, Craig J. Thomas, James Inglese, Noel T. Southall, Steven Titus, Wei Zheng, Wenwei Huang, Gerd Krause, Gunnar Kleinau
-
Patent number: 7126403Abstract: A new clock driver is described for the use in the phase detector of a clock and data recovery circuit (CDR). By building a resonant LC tank, whose center frequency is similar to the clock frequency, a low power clock driver is realized. A method based upon minimizing power consumption is described for determining the value of the programmable capacitance. A programmable capacitance adjusts the center frequency of the tank so it matches the frequency of the clock and a finite state machine at startup determines the value of this programmable capacitance. A criterion for tuning the center frequency of the tank is to choose the capacitance which leads to the lowest power consumption. A low Q tank affords a reasonable compromise between power efficiency and performance in the CDR circuit.Type: GrantFiled: November 1, 2004Date of Patent: October 24, 2006Assignee: Analog Devices, Inc.Inventors: John G. Kenney, Jr., Viswabharath Reddy, Ward Steven Titus
-
Patent number: 6087488Abstract: Novel genes in the erg subfamily of potassium channel proteins in humans are described. This family of proteins, and the genes encoding the proteins, are implicated in the development of long Q-T syndrome, a rare, but often fatal, cardiac arrhythmia.Type: GrantFiled: July 12, 1999Date of Patent: July 11, 2000Assignee: Wisconsin Alumni Research FoundationInventors: Barry S. Ganetzky, Steven A. Titus
-
Patent number: 5986081Abstract: Novel genes in the erg subfamily of potassium channel proteins in humans are described. This family of proteins, and the genes encoding the proteins, are implicated in the development of long Q-T syndrome rare, but often fatal, cardiac arrhythmia.Type: GrantFiled: October 22, 1997Date of Patent: November 16, 1999Assignee: Wisconsin Alumni Research FoundationInventors: Barry S. Ganetzky, Steven A. Titus